Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Cancer 9, 768–769 (1 November 2009) | doi:10.1038/nrc2751
Therapeutic resistance: Smoothing the way
Abstract
There is a compelling rationale for using hedgehog pathway inhibitors to treat both medulloblastoma and basal cell carcinoma. Phase I clinical trial data in basal cell carcinoma and a case study of a patient with medulloblastoma reported recently in the New England Journal of Medicine have shown that GDC-0449, which inhibits hedgehog signalling by binding to the smoothened (SMO) receptor, exhibits anti-tumour activity.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
